HB0017
- Generic Name
- HB0017
A Phase 2 Study to Explore the Efficacy and Safety of HB0017 Longer Dose Interval in Psoriasis Patients
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06592274
- Locations
- 🇨🇳
Shandong First Medical University Affiliated Dermatology Hospital, Jinan, Shandong, China
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05531682
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
🇨🇳Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, China
A Study of Injection HB0017 in Adult Healthy Volunteers
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04505033
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath